QCG
LFCR icon

Quadrant Capital Group’s Lifecore Biomedical LFCR Stock Holding History

Quadrant Capital Group’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,678
Closed -$6.24K – 1975
2026
Q1 		$6.24K Sell
1,678
-215
-11% -$1.49K ﹤0.01% 2310
2025
Q4 		$15.5K Sell
1,893
-37
-2% -$274 ﹤0.01% 2086
2025
Q3 		$14.2K Buy
+1,930
New +$14.6K ﹤0.01% 2060
2025
Q2 		– Sell
-2,023
Closed -$14.3K – 2036
2025
Q1 		$14.3K Sell
2,023
-63
-3% -$392 ﹤0.01% 2134
2024
Q4 		$15.5K Hold
2,086
– – ﹤0.01% 1987
2024
Q3 		$10.3K Sell
2,086
-330
-14% -$1.72K ﹤0.01% 2135
2024
Q2 		$12.4K Hold
2,416
– – ﹤0.01% 2040
2024
Q1 		$12.8K Hold
2,416
– – ﹤0.01% 2015
2023
Q4 		$15K Hold
2,416
– – ﹤0.01% 1921
2023
Q3 		$18.2K Hold
2,416
– – ﹤0.01% 1750
2023
Q2 		$23.4K Hold
2,416
– – ﹤0.01% 1640
2023
Q1 		$9.12K Buy
+2,416
New +$13.5K ﹤0.01% 2065
2019
Q4 		– Sell
-78
Closed – – 2455
2019
Q3 		$0 Buy
+78
New +$849 ﹤0.01% 2349

Other funds holding LFCR

WC
Wynnefield Capital New York $145M AUM 14.57% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $154M AUM 15.9% 1-Year Est. Return
3C
325 Capital New York $419M AUM 75.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $2.16B AUM 28.56% 1-Year Est. Return

Quadrant Capital Group's LFCR Position: Q2 2026 in Review

Quadrant Capital Group sold out of Lifecore Biomedical (LFCR) in Q2 2026, closing a stake of 1,678 shares — an estimated $6.24K sold.

Quadrant Capital Group first reported a position in LFCR in Q3 2019 and held it in 13 quarters. The position peaked at $23.4K in Q2 2023. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Quadrant Capital Group reported no remaining Lifecore Biomedical position as of Q2 2026 after selling out during the quarter.
  • Quadrant Capital Group sold 1,678 Lifecore Biomedical shares in Q2 2026, an estimated $6.24K.
  • Quadrant Capital Group first reported a position in Lifecore Biomedical in Q3 2019 and held it in 13 quarters.
  • Quadrant Capital Group's Lifecore Biomedical position peaked at $23.4K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Quadrant Capital Group's 13F filing for Q2 2026, filed 14 Aug 2026.